CAM
BPMC

Cresset Asset Management’s Blueprint Medicines BPMC Stock Holding History

Cresset Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,926
Closed -$529K – 1010
2021
Q4 		$529K Buy
+4,926
New +$515K 0.01% 680

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Cresset Asset Management's BPMC Position: Q1 2022 in Review

Cresset Asset Management sold out of Blueprint Medicines (BPMC) in Q1 2022, closing a stake of 4,926 shares — an estimated $529K sold.

Cresset Asset Management first reported a position in BPMC in Q4 2021 and held it in 1 quarter. The position peaked at $529K in Q4 2021. 248 funds tracked by Wall St. Rank hold BPMC as of Q1 2022.

  • Cresset Asset Management reported no remaining Blueprint Medicines position as of Q1 2022 after selling out during the quarter.
  • Cresset Asset Management sold 4,926 Blueprint Medicines shares in Q1 2022, an estimated $529K.
  • Cresset Asset Management first reported a position in Blueprint Medicines in Q4 2021 and held it in 1 quarter.
  • Cresset Asset Management's Blueprint Medicines position peaked at $529K in Q4 2021.
  • 248 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2022.

Based on Cresset Asset Management's 13F filing for Q1 2022, filed 16 May 2022.